Curis drops after FDA partial clinical hold on blood disorder therapy trial

Curis

04/04/2022 12:59

** Shares of cancer drug developer  CRIS.O  slump about 31%
to $1.68 premarket following a partial clinical hold by U.S. FDA
    ** Stock, down nearly 49% YTD to last close, set for its
lowest in over a year if losses hold to open
    ** FDA places a partial clinical hold on company's
early-to-mid-stage study of its drug candidate, emavusertib, for
patients who have relapsed or are resistant to treatment for
acute myeloid leukemia (AML) or high-risk myelodysplastic
syndrome  urn:newsml:reuters.com:*:nPnbGVmDZa
    ** AML is a cancer affecting the blood and bone marrow,
while myelodysplastic syndrome is caused by poorly formed blood
cells
    ** CRIS says regulator has sought safety and other data,
including the death of an AML patient who experienced
rhabdomyolysis or muscle tissue breakdown, among other
conditions 
    ** Rhabdomyolysis has previously been identified as a
dose-limiting toxicity of emavusertib - CRIS
    ** Says confident in the potential of emavusertib and
committed to working with the FDA 
    

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))